Reviva Reports the Completion of Patient Enrolment in the P-III Study (RECOVER) of Brilaroxazine for Schizophrenia
Shots:
- The patient’s enrolment has been completed in the P-III study (RECOVER) evaluating brilaroxazine (15/50mg, qd for 28 days) vs PBO in 402 patients at multiple sites in the US, EU & Asia. The results are expected in Oct 2023
- The 1EPs of the study is a decrease in Positive and Negative Symptoms Assessment total score vs PBO from baseline to Day 28 while 2EPs incl. clinical global impression (CGI) rating scale, positive and negative symptoms, social functioning & cognition, demonstrate a well-tolerated safety profile with no cardiac or metabolic side effects as seen in P-II trial
- Additionally, a 1yr. OLE study with flexible doses of 15,30,50mg will evaluate the long-term safety & tolerability of brilaroxazine for stable schizophrenia
Ref: Globe Newswire | Image: Reviva
Related News:- Reviva Reports First Patient Dosing in P-III Study of Brilaroxazine for the Treatment of Schizophrenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
